GENINUS Inc. (KOSDAQ:389030)

Market Cap	54.73B
Revenue (ttm)	6.46B
Net Income (ttm)	-12.27B
Shares Out	33.35M
EPS (ttm)	-368.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,603
Average Volume	708,073
Open	1,696.00
Previous Close	1,635.00
Day's Range	1,571.00 - 1,700.00
52-Week Range	1,080.00 - 1,981.00
Beta	0.64
RSI	66.74
Earnings Date	May 15, 2025

About GENINUS

GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of next generation sequencing (NGS) - based genome analysis solutions in South Korea. It offers CancerSCAN, an NGS-based cancer genome diagnosis solution; LiquidSCAN, a liquid biopsy NGS test; and Celinus, a single-cell analysis solution for ultra-precise genome analysis. The company also provides HealthSCAN, a genetic test service; WithMe, a service that analyzes gut bacteria characteristics related to the risk of chronic diseases; a...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 389030

Financial Performance

In 2024, GENINUS's revenue was 6.46 billion, a decrease of -7.35% compared to the previous year's 6.97 billion. Losses were -12.27 billion, 26.7% more than in 2023.